DOCK1 and hepatocellular carcinoma: Collectively, our findings demonstrate that DOCK1 levels largely determine whether metformin will be an effective therapy for individual HCC patients, and that DOCK1 targeting is a promising strategy for sensitizing liver cancer cells to metformin.